Industry executives agree that the Inflation Reduction Act (IRA) has significant potential to impact the value of biopharmaceutical assets and portfolios.  However, there is also a significant amount of uncertainty regarding the ultimate impact of the IRA and how markets will evolve over time.  The effects of the IRA are complex, differing across therapeutic categories, types of molecules, stages of development and other factors.  New product planning teams are faced with the immediate need to revisit forecasts for pipeline and inline products, as well as evaluate a variety of possible scenarios and contingencies. In this session we will: